Clinical Scorecard: FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

At a Glance

Key Highlights

• Secukinumab is the only IL-17A inhibitor approved for pediatric HS.
• Approval expands treatment options for adolescents with limited therapies.
• HS is characterized by recurrent, painful nodules and potential scarring.
• More than half of HS patients experience symptom onset during adolescence.
• Diagnosis of HS may be delayed for up to 10 years.

Guideline-Based Recommendations

Diagnosis

• Consider HS in adolescents presenting with recurrent painful nodules.

Management

• Utilize secukinumab as a treatment option for moderate to severe HS.

Monitoring & Follow-up

• Monitor for treatment efficacy and potential side effects.

Risks

• Potential for delayed diagnosis leading to prolonged suffering.

Patient & Prescribing Data

Adolescents aged 12 years and older with moderate to severe HS.

Weight-based dosing in patients over 30 kg yields comparable drug exposure to adults.

Clinical Best Practices

• Educate patients and families about HS and treatment options.
• Encourage early diagnosis to improve management outcomes.
• Monitor patients for signs of treatment response and adverse effects.

Related Resources & Content

• Novartis Press Release